Nisha S. Joseph

1.5k total citations
69 papers, 783 citations indexed

About

Nisha S. Joseph is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Nisha S. Joseph has authored 69 papers receiving a total of 783 indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Hematology, 33 papers in Oncology and 32 papers in Molecular Biology. Recurrent topics in Nisha S. Joseph's work include Multiple Myeloma Research and Treatments (55 papers), Protein Degradation and Inhibitors (21 papers) and Cancer Treatment and Pharmacology (12 papers). Nisha S. Joseph is often cited by papers focused on Multiple Myeloma Research and Treatments (55 papers), Protein Degradation and Inhibitors (21 papers) and Cancer Treatment and Pharmacology (12 papers). Nisha S. Joseph collaborates with scholars based in United States, India and Italy. Nisha S. Joseph's co-authors include Sagar Lonial, Jonathan L. Kaufman, Ajay K. Nooka, Madhav V. Dhodapkar, Vikas A. Gupta, Lawrence Boise, Craig C. Hofmeister, Leonard T. Heffner, Charise Gleason and Leonard T. Heffner and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

Nisha S. Joseph

56 papers receiving 774 citations

Peers

Countries citing papers authored by Nisha S. Joseph

Since Specialization

Citations

This map shows the geographic impact of Nisha S. Joseph's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nisha S. Joseph with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nisha S. Joseph more than expected).

Fields of papers citing papers by Nisha S. Joseph

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nisha S. Joseph. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nisha S. Joseph. The network helps show where Nisha S. Joseph may publish in the future.

Co-authorship network of co-authors of Nisha S. Joseph

This figure shows the co-authorship network connecting the top 25 collaborators of Nisha S. Joseph. A scholar is included among the top collaborators of Nisha S. Joseph based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nisha S. Joseph. Nisha S. Joseph is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract 2025 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Danielle Roberts, Vikas A. Gupta, Nisha S. Joseph, Craig C. Hofmeister, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka, Jonathan L. Kaufman	0
2	Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at 2 Institutes 2025 ·Clinical Lymphoma Myeloma & Leukemia ·Cindy Varga, Myra Robinson, Vikas A. Gupta, Craig C. Hofmeister, Ajay K. Nooka, Jonathan L. Kaufman, Madhav V. Dhodapkar, Sagar Lonial, (unknown), Christopher J. Ferreri, (unknown), Shebli Atrash, Manisha Bhutani, Peter M. Voorhees, Nisha S. Joseph	0
3	Immune-aging is linked to clinical malignancy, racial ancestry, and vaccine responses in myeloma 2025 ·Blood Advances ·(unknown), (unknown), (unknown), (unknown), (unknown), Nisha S. Joseph, Jonathan L. Kaufman, Craig C. Hofmeister, Vikas A. Gupta, Sagar Lonial, Ajay K. Nooka, Kavita M. Dhodapkar, Madhav V. Dhodapkar	2
4	Talquetamab bridging therapy for B-cell maturation antigen chimeric antigen receptor T-cell in Relapsed/Refractory multiple myeloma 2025 ·Blood ·(unknown), Ajay K. Nooka, Jonathan L. Kaufman, Craig C. Hofmeister, Vikas A. Gupta, (unknown), Nishi Shah, Sagar Lonial, Nisha S. Joseph	0
5	Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience 2025 ·Haematologica ·(unknown), (unknown), Danielle Roberts, Nisha S. Joseph, Craig C. Hofmeister, Vikas A. Gupta, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka, Jonathan L. Kaufman	0
6	Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity 2024 ·npj Vaccines ·Alberto Moreno, Kelly E. Manning, (unknown), Ajay K. Nooka, Madison Ellis, (unknown), Jeffrey M. Switchenko, Bushra Wali, Jonathan L. Kaufman, Craig C. Hofmeister, Nisha S. Joseph, Sagar Lonial, Kavita M. Dhodapkar, Madhav V. Dhodapkar, Mehul S. Suthar	0
7	Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients 2024 ·Blood Cancer Journal ·Nisha S. Joseph, Jonathan L. Kaufman, (unknown), Craig C. Hofmeister, Madhav V. Dhodapkar, Lawrence Boise, (unknown), Danielle Roberts, Ajay K. Nooka, Sagar Lonial	5
8	Risk of Infections in Multiple Myeloma Patients Treated with Bispecific Antibodies 2024 ·Blood ·(unknown), (unknown), Nisha S. Joseph, Craig C. Hofmeister, Vikas A. Gupta, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka, Jonathan L. Kaufman	3
9	Iberdomide Alone or in Combination with Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma (SMM) 2024 ·Blood ·Nisha S. Joseph, Jonathan L. Kaufman, Craig C. Hofmeister, Vikas A. Gupta, (unknown), (unknown), Ajay K. Nooka, Madhav V. Dhodapkar, Sagar Lonial	1
10	Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib Induction 2023 ·JCO Oncology Practice ·(unknown), (unknown), (unknown), Yuan Liu, (unknown), Nisha S. Joseph, Craig C. Hofmeister, Jonathan L. Kaufman, Madhav V. Dhodapkar, Ajay K. Nooka, Sagar Lonial, R. Donald Harvey	7
11	Efficacy of D-RVD Vs RVD Among t(11;14) Patients with Newly Diagnosed Myeloma 2023 ·Blood ·Jonathan L. Kaufman, Nisha S. Joseph, Vikas A. Gupta, (unknown), Danielle Roberts, Craig C. Hofmeister, Madhav V. Dhodapkar, Ajay K. Nooka, Sagar Lonial, Lawrence Boise	1
12	A Randomized Phase II Study of Daratumumab, Ixazomib, and Dexamethasone (DId, Arm A) Vs Daratumumab, Bortezomib and Dexamethasone (DVd) Followed By Daratumumab, Did (Arm B) in Newly Diagnosed Multiple Myeloma (DeRIVE) Study 2023 ·Blood ·Ajay K. Nooka, Nisha S. Joseph, Vikas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, (unknown), (unknown), (unknown), Annelore Cortoos, Thomas S. Lin, Richard Labotka, Stephen J. Noga, Jonathan L. Kaufman, Sagar Lonial	1
13	Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia 2021 ·Blood Cancer Discovery ·Akhilesh Kaushal, Ajay K. Nooka, (unknown), Katherine E. Pendleton, Benjamin G. Barwick, (unknown), Samuel S. McCachren, Vikas A. Gupta, Nisha S. Joseph, Craig C. Hofmeister, Jonathan L. Kaufman, Leonard T. Heffner, Stephen M. Ansell, Lawrence Boise, Sagar Lonial, Kavita M. Dhodapkar, Madhav V. Dhodapkar	14
14	Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma 2020 ·Journal of Clinical Oncology ·Nisha S. Joseph, Jonathan L. Kaufman, Madhav V. Dhodapkar, Craig C. Hofmeister, (unknown), Leonard T. Heffner, Vikas A. Gupta, Lawrence Boise, Sagar Lonial, Ajay K. Nooka	132
15	769P APOBEC signatures and high tumour mutational burden as predictors of clinical outcomes and response to therapy in patients with urothelial carcinoma 2020 ·Annals of Oncology ·(unknown), Li Zhang, (unknown), Patrick Devine, Bradley A. Stohr, James P. Grenert, Jessica Van Ziffle, Nisha S. Joseph, Boris C. Bastian, Sarah E. Umetsu, Courtney Onodera, Elaine S. Chan, Arpita Desai, Sima P. Porten, Jonathan Chou, Terence W. Friedlander, (unknown), Eric J. Small, E. Alejandro Sweet‐Cordero, Vadim S. Koshkin	1
16	Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone 2019 ·Blood Cancer Journal ·Timothy M. Schmidt, Benjamin G. Barwick, Nisha S. Joseph, Leonard T. Heffner, Craig C. Hofmeister, (unknown), Madhav V. Dhodapkar, Vikas A. Gupta, David L. Jaye, Jiayi Wu, Subir Goyal, Zhengjia Chen, Lawrence Boise, Sagar Lonial, Ajay K. Nooka, Jonathan L. Kaufman	108
17	Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents 2018 ·Cancer ·Roberto Mina, Nisha S. Joseph, Jonathan L. Kaufman, Vikas A. Gupta, Leonard T. Heffner, Craig C. Hofmeister, Lawrence Boise, Madhav V. Dhodapkar, Charise Gleason, Ajay K. Nooka, Sagar Lonial	34
18	Novel Approaches for the Management of AL Amyloidosis 2018 ·Current Hematologic Malignancy Reports ·Nisha S. Joseph, Jonathan L. Kaufman	8
19	Lenalidomide, Bortezomib, and Dexamethasone (RVD) As Induction Therapy in Newly Diagnosed Multiple Myeloma (MM) 2017 ·Blood ·Nisha S. Joseph, (unknown), Charise Gleason, Leonard T. Heffner, Lawrence Boise, Jonathan L. Kaufman, Sagar Lonial, Ajay K. Nooka	0
20	High-risk Multiple Myeloma: Definition and Management 2017 ·Clinical Lymphoma Myeloma & Leukemia ·Nisha S. Joseph, Silvia Gentili, Jonathan L. Kaufman, Sagar Lonial, Ajay K. Nooka	32

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact